The integration of MEK inhibitors with OVs, exemplified by trametinib in conjunction with T-VEC, demonstrates synergistic enhancement of melanoma cell cytotoxicity in vitro, attenuated tumor progression in vivo, and prolonged survival outcomes in murine models. The gene discussed is MAP2K7; the disease is melanoma.